Feb 23 (Reuters) - JCR Pharmaceuticals Co Ltd :
* Says it plans to initiate development of a new drug candidate, JR-162
* Says JR-162 is a blood-brain barrier (BBB)-penetrating acid alpha-glucosidase (GAA) for treating Pompe disease which uses J-Brain Cargo, JCR’s BBB penetration technology
Source text in Japanese: goo.gl/Pf2eYc
Further company coverage: (Beijing Headline News)
Our Standards: The Thomson Reuters Trust Principles.